As healthcare facilities and pharmacies try to recover from one of the most disruptive cyberattacks in US history, reports have emerged that the perpetrators may have rece
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh